Bangkok Genomics Innovation Stock

Equities

BKGI

THB972010003

Biotechnology & Medical Research

End-of-day quote Thailand S.E. 06:00:00 2024-05-09 pm EDT 5-day change 1st Jan Change
2.94 THB -1.34% Intraday chart for Bangkok Genomics Innovation +0.68% 0.00%
1 week+0.68%
Current month-8.12%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2024 * - Sales 2025 * - Capitalization 1.76B 64.86B
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees -
Yield 2024 *
1.36%
Yield 2025 *
-
Free-Float 96.47%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.34%
1 week+0.68%
Current month-8.12%
1 month-0.68%
More quotes
1 week
2.80
Extreme 2.8
3.14
1 month
2.56
Extreme 2.56
3.54
Current year
2.14
Extreme 2.14
5.65
1 year
2.14
Extreme 2.14
5.65
3 years
2.14
Extreme 2.14
5.65
5 years
2.14
Extreme 2.14
5.65
10 years
2.14
Extreme 2.14
5.65
More quotes
Managers TitleAgeSince
Chief Executive Officer - 17-08-31
Director/Board Member - 18-12-31
Members of the board TitleAgeSince
Chairman 63 22-01-27
Director/Board Member 42 22-01-27
- -
More insiders
Date Price Change Volume
24-05-10 2.94 -1.34% 7,626,198
24-05-09 2.98 -3.25% 8,227,656
24-05-08 3.08 +0.65% 6,556,986
24-05-07 3.06 +4.79% 12,310,780

End-of-day quote Thailand S.E., May 09, 2024

More quotes
Bangkok Genomics Innovation Public Company Limited is a Thailand-based company that operates laboratories and provides medical analysis services. The Company provides reproductive health screening services, including screening for fetal chromosomal abnormalities from maternal blood using the NIFTY brand using Next-Generation Sequencing (NGS) technology combined with other technology to screen for chromosomal abnormalities in babies such as down syndrome to reduce the risk of miscarriage from unnecessary amniocentesis. Its other screening tests include COLOTECT Colon Cancer Screening and DNALL Personal DNA Testing. Its technology services include DNA base sequencing, RNA base sequencing and metabolism and protein omics. It also contributes to the provision of various research services, both medical and other aspects. Its customers include government customers, such as medical schools, health centers, as well as private sector customers, such as clinics, hospitals and others.
More about the company

Annual profits - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW